Candel Therapeutics Inc [NASDAQ: CADL] price surged by 16.62 percent to reach at $1.74.
The one-year CADL stock forecast points to a potential upside of 38.18. The average equity rating for CADL stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Candel Therapeutics Inc [CADL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CADL shares is $19.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CADL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Candel Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on Feb-21-25. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on February 19, 2025, representing the official price target for Candel Therapeutics Inc stock. Previously, the target price had yet another raise to $15, while BofA Securities analysts kept a Buy rating on CADL stock.
CADL Stock Performance Analysis:
Candel Therapeutics Inc [CADL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.81. With this latest performance, CADL shares gained by 84.86% in over the last four-week period, additionally plugging by 132.57% over the last 6 months – not to mention a rise of 609.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CADL stock in for the last two-week period is set at 79.56, with the RSI for the last a single of trading hit 88.08, and the three-weeks RSI is set at 72.99 for Candel Therapeutics Inc [CADL]. The present Moving Average for the last 50 days of trading for this stock 7.91, while it was recorded at 10.01 for the last single week of trading, and 6.89 for the last 200 days.
Insight into Candel Therapeutics Inc Fundamentals:
Candel Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.18 and a Current Ratio set at 1.18.
CADL Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CADL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Candel Therapeutics Inc go to 0.88%.
Candel Therapeutics Inc [CADL] Institutonal Ownership Details
The top three institutional holders of CADL stocks are: NORTHPOND VENTURES, LLC with ownership of 1.94 million shares, which is approximately 6.477%. BLACKROCK INC., holding 0.82 million shares of the stock with an approximate value of $$5.1 million in CADL stocks shares; and BLACKROCK INC., currently with $$5.08 million in CADL stock with ownership which is approximately 2.8035%.
